Suggested remit: To appraise the clinical and cost effectiveness of resmetirom and semaglutide within its marketing authorisation for treating liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis (MASH).
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6458
Provisional Schedule
- Committee meeting:
- 17 June 2026
- Expected publication:
- 26 August 2026
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
Stakeholders
- Companies sponsors
- Novo Nordisk Ltd
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- All About Obesity
- British Liver Trust
- British Obesity Society
- Diabetes UK
- GUTS UK
- HEART UK
- Hemochromotosis UK
- Liver4Life
- LIVErNORTH
- National Obesity Forum
- Network of Sikh Organisations
- Obesity Empowerment Network
- Obesity Health Alliance
- Obesity UK
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Professional groups
- Association for the Study of Obesity
- British Association for the Study of the Liver (BASL)
- British Dietetic Association
- British Geriatrics Society
- British Hepatology Pharmacy Group
- British Nutrition Foundation
- British Society for Paediatric Endocrinology and Diabetes
- British Society of Gastroenterology
- Faculty of Public Health
- Hepatitis Nurse Specialist Forum
- Neonatal and Paediatric Pharmacists Group
- Nutrition Society
- Obesity Management Association
- Royal College of Emergency Medicine
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for Endocrinology
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Alliance Pharmaceuticals (vitamin E)
- Brown & Burk UK (pioglitazone)
- Kora Healthcare (vitamin E)
- Madrigal Pharmaceuticals (resmetirom)
- Mylan (pioglitazone)
- Neon Healthcare (pioglitazone)
- Sandoz (pioglitazone)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 November 2025 | Invitation to participate |
| 09 July 2025 | This evaluation will now go ahead as a Single Technology Appraisal (STA). This evaluation will only cover semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis. The evaluation will begin in early November 2025. |
| 17 April 2025 - 20 May 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6458 |
| 15 May 2025 | NICE is currently consulting on the draft scope for the partial update of our Non-alcoholic fatty liver disease: assessment and management guideline (NG49). As part of this update, we will use the term ‘metabolic dysfunction-associated steatotic liver disease’ (MASLD) instead of ‘non-alcoholic fatty liver disease’ (NAFLD) in the title and throughout the guideline. See the in development page for more details about the draft scope consultation which closes on 01 June 2025 at 11:59pm. |
| 17 April 2025 | In progress. Scoping commencing |
| 11 April 2025 | This topic will now be progressed as a Multiple Technology Appraisal (MTA) alongside the following topic; Resmetirom for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6529] The Invitation to Participate (ITP) will now be issued week commencing 07 July 2025 and the MTA title and ID number is: Resmetirom and semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6458] |
| 12 December 2024 | Referral |
| 29 November 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 29 November 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual